The neurofibromatosis type 1 gene encodes a protein related to GAP

doi:10.1016/0092-8674(90)90024-9

Cell

Volume 62, Issue 3, 10 August 1990, Pages 599-608

https://doi.org/10.1016/0092-8674(90)90024-9 Get rights and content

Abstract

cDNA walking and sequencing have extended the open reading frame for the neurofibromatosis type 1 gene (NF1). The new sequence now predicts 2485 amino acids of the NF1 peptide. A 360 residue region of the new peptide shows significant similarity to the known catalytic domains of both human and bovine GAP (GTPase activating protein). A much broader region, centered around this same 360 amino acid sequence, is strikingly similar to the yeast IRA1 product, which has a similar amino acid sequence and functional homology to mammalian GAP. This evidence suggests that NF1 encodes a cytoplasmic GAP-like protein that may be involved in the control of cell growth by interacting with proteins such as the RAS gene product. Mapping of the cDNA clones has confirmed that NF1 spans a t(1;17) translocation mutation and that three active genes lie within an intron of NF1, but in opposite orientation.

References (39)

R. Ballester et al.
Genetic analysis of mammalian GAP expressed in yeast
Cell
(1989)
R.M. Cawthon et al.
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
Cell
(1990)
J.R. Feramisco et al.
Optimal spatial requirements for the location of basic residues in peptide substrates for the cyclic AMP-dependent protein kinase
J. Biol. Chem.
(1980)
A. Hall
ras and GAP—who's controlling whom?
Cell
(1990)
D.R. Kaplan et al.
PDGF β-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex
Cell
(1990)
H. Kitayama et al.
A ras-related gene with transformation suppressor activity
Cell
(1989)
J. Kyte et al.
A simple method for displaying the hydropathic character of a protein
J. Mol. Biol.
(1982)
B. Levinson et al.
A transcribed gene in an intron of the human factor VIII gene
Genomics
(1990)
A.G. Menon et al.
Characterization of a translocation within the von Recklinghausen neurofibromatosis region of chromosome 17
Genomics
(1989)
W.R. Pearson
Rapid and sensitive sequence comparison with FASTP and FASTA
Meth. Enzymol.
(1990)

K. Tanaka et al.

S. cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating protein

Cell

(1990)

T. Toda et al.

In yeast, RAS proteins are controlling elements of adenylate cyclase

Cell

(1985)

D. Viskochil et al.

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus

Cell

(1990)

H. Adari et al.

Guanosine triphosphate activating protein (GAP) interacts with the p21 ras effector binding domain

Science

(1988)

D. Benton

Recent changes in the GenBank on-line service

Nucl. Acids Res.

(1990)

W.D. Benton et al.

Screening lambda-gt recombinant clones by hybridization to single plaques in situ

Science

(1977)

C. Cáles et al.

The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product

Nature

(1988)

J. Devereux et al.

A comprehensive set of sequence analysis programs for the VAX

Nucl. Acids Res.

(1984)

C. Ellis et al.

Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases

Nature

(1990)

Cited by (1000)

Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods
2024, Journal of the American Academy of Dermatology
People with Neurofibromatosis Type 1 (NF1) suffer disfigurement and pain when hundreds to thousands of cutaneous neurofibromas (cNFs) appear and grow throughout life. Surgical removal of cNFs under anesthesia is the only standard therapy, leaving surgical scars.
Effective, minimally-invasive, safe, rapid, tolerable treatment(s) of small cNFs that may prevent tumor progression.
Safety, tolerability, and efficacy of 4 different treatments were compared in 309, 2-4 mm cNFs across 19 adults with Fitzpatrick skin types (FST) I-IV: radiofrequency (RF) needle coagulation, 755 nm alexandrite laser with suction, 980 nm diode laser, and intratumoral injection of 10 mg/mL deoxycholate. Regional pain, clinical responses, tumor height and volume (by 3D photography) were assessed before, 3 and 6 months post-treatment. Biopsies were obtained electively at 3 months.
There was no scarring or adverse events > grade 2. Each modality significantly (P < .05) reduced or cleared cNFs, with large variation between tumors and participants. Alexandrite laser and deoxycholate were fast and least painful; 980 nm laser was most painful. Growth of cNFs was not stimulated by treatment(s) based on height and volume values at 3 and 6 months compared to baseline.
Intervention was a single treatment session; dosimetry has not been optimized.
Small cNFs can be rapidly and safely treated without surgery.
Droplet Digital PCR for Fast and Accurate Characterization of NF1 Locus Deletions: Confirmation of the Predominant Maternal Origin of Type-1 Deletions
2024, Journal of Molecular Diagnostics
Neurofibromatosis type-1 is a genetic disorder caused by loss-of-function variants in the tumor-suppressor NF1. Approximately 4% to 11% of neurofibromatosis type-1 patients have a NF1 locus complete deletion resulting from nonallelic homologous recombination between low copy repeats. Codeleted genes probably account for the more severe phenotype observed in NF1-deleted patients. This genotype–phenotype correlation highlights the need for a detailed molecular description. A droplet digital PCR (ddPCR) set along the NF1 locus was designed to delimitate the three recurrent NF1 deletion breakpoints. The ddPCR was tested in 121 samples from nonrelated NF1-deleted patients. Classification based on ddPCR versus multiplex ligation-dependent probe amplification (MLPA) was compared. In addition, microsatellites were analyzed to identify parental origin of deletions. ddPCR identified 77 type-1 (64%), 20 type-2 (16%), 7 type-3 (6%), and 17 atypical deletions (14%). The results were comparable with MLPA, except for three atypical deletions misclassified as type-2 using MLPA, for which the SUZ12 gene was not deleted. A significant maternal bias (25 of 30) in the origin of deletions was identified. This study proposes a fast and efficient ddPCR quantification to allow fine NF1 deletion classification. It indicates that ddPCR can be implemented easily into routine diagnosis to complement the techniques dedicated to NF1 point variant identification. This new tool may help unravel the genetic basis conditioning phenotypic variability in NF1-deleted patients and offer tailored genetic counseling.
Direct comparison of the diagnostic accuracy of 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose PET/CT and MRI for the differentiation of malignant peripheral nerve sheath tumour in neurofibromatosis type I: a meta-analysis
2024, Clinical Radiology
To compare the diagnostic test of integrated 2-[¹⁸F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (FDG PET/CT) with that of magnetic resonance imaging (MRI) for the differentiation of malignant peripheral nerve sheath tumours (MPNSTs) in neurofibromatosis type 1 (NF1) patients.
A systematic search was performed in PubMed and EMBASE (last updated in 30 November 2022). Studies investigating the performance of FDG PET/CT and MRI for differentiation of MPNSTs were eligible for inclusion. Only studies reporting a direct comparison between these imaging methods were considered to establish precise summary estimates in the same setting of patients.
The pooled estimate of sensitivity of FDG PET/CT was 0.99 and a pooled specificity of 0.53. The pooled estimate of sensitivity of MRI was 0.85 and a pooled specificity of 0.85.
Analysis of the available studies indicated that FDG PET/CT and MRI had similar diagnostic performances for differentiation of MPNSTs in patients with NF1; however, either technique can be a complement to the other rather than being used singly.
Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1
2024, Laboratory Investigation
Cutaneous neurofibromas (cNFs) are characteristic of neurofibromatosis 1 (NF1), yet their immune microenvironment is incompletely known. A total of 61 cNFs from 10 patients with NF1 were immunolabeled for different types of T cells and macrophages, and the cell densities were correlated with clinical characteristics. Eight cNFs and their overlying skin were analyzed for T cell receptor CDR domain sequences, and mass spectrometry of 15 cNFs and the overlying skin was performed to study immune-related processes. Intratumoral T cells were detected in all cNFs. Tumors from individuals younger than the median age of the study participants (33 years), growing tumors, and tumors smaller than the data set median showed increased T cell density. Most samples displayed intratumoral or peritumoral aggregations of CD3-positive cells. T cell receptor sequencing demonstrated that the skin and cNFs host distinct T cell populations, whereas no dominant cNF-specific T cell clones were detected. Unique T cell clones were fewer in cNFs than in skin, and mass spectrometry suggested lower expression of proteins related to T cell-mediated immunity in cNFs than in skin. CD163-positive cells, suggestive of M2 macrophages, were abundant in cNFs. Human cNFs have substantial T cell and macrophage populations that may be tumor-specific.
Predicting IHC staining classes of NF1 using features in the hematoxylin channel
2023, Journal of Pathology Informatics
Immunohistochemistry (IHC) highlights specific cell types in tissues and traditionally involves antibody staining together with a hematoxylin counterstain. The intensity and pattern of hematoxylin staining differs between cell types and reveals morphological characteristics of cells. Here, we propose that features in the hematoxylin stain can be used to predict IHC labels, such as Neurofibromin (encoded by the gene NF1). The dataset consists of 7.2 million cells from benign and kidney cancer cores in a tissue microarray. Morphology and hematoxylin (H&M) features defined within QuPath are subjected to a clustering analysis in CytoMap. H&M features are also used to train 4 different XGBoost models to predict high, low, and negative NF1 stain classes in benign renal tubules, clear cell (ccRCC), papillary (PRCC), and chromophobe (ChRCC) renal carcinoma. The prediction accuracies of NF1 staining classes in benign, ccRCC, ChRCC, and PRCC range between 70% and 90% with areas under the precision recall curve PRAUC_NF1-high = 0.82+0.12, PRAUC_NF1-low = 0.62+0.25, and PRAUC_NF1-negative = 0.83+0.16. The most important feature for predicting the NF1 class involves the minimum cellular hematoxylin staining intensity. Together, these results demonstrate the feasibility to predict NF1 expression solely from features in hematoxylin staining using open source software. Since the hematoxylin features can be obtained from regular H&E and IHC slides, the proposed workflow has broad applicability.
NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma
2022, Cell Reports
A long-standing question in the pancreatic ductal adenocarcinoma (PDAC) field has been whether alternative genetic alterations could substitute for oncogenic KRAS mutations in initiating malignancy. Here, we report that Neurofibromin1 (NF1) inactivation can bypass the requirement of mutant KRAS for PDAC pathogenesis. An in-depth analysis of PDAC databases reveals various genetic alterations in the NF1 locus, including nonsense mutations, which occur predominantly in tumors with wild-type KRAS. Genetic experiments demonstrate that NF1 ablation culminates in acinar-to-ductal metaplasia, an early step in PDAC. Furthermore, NF1 haploinsufficiency results in a dramatic acceleration of Kras^G12D-driven PDAC. Finally, we show an association between NF1 and p53 that is orchestrated by PML, and mosaic analysis with double markers demonstrates that concomitant inactivation of NF1 and Trp53 is sufficient to trigger full-blown PDAC. Together, these findings open up an exploratory framework for apprehending the mechanistic paradigms of PDAC with normal KRAS, for which no effective therapy is available.

View all citing articles on Scopus

View full text

Cell

ArticleThe neurofibromatosis type 1 gene encodes a protein related to GAP

Abstract

Cell

Cell

J. Biol. Chem.

Cell

Cell

Cell

J. Mol. Biol.

Genomics

Genomics

Meth. Enzymol.

Cell

Cell

Cell

Guanosine triphosphate activating protein (GAP) interacts with the p21 ras effector binding domain

Science

Recent changes in the GenBank on-line service

Nucl. Acids Res.

Screening lambda-gt recombinant clones by hybridization to single plaques in situ

Science

The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product

Nature

A comprehensive set of sequence analysis programs for the VAX

Nucl. Acids Res.

Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases

Nature

Article
The neurofibromatosis type 1 gene encodes a protein related to GAP